Wide Ranks

IMVT

Immunovant, Inc.

28.73

Top Statistics
Market Cap 4 B Forward PE -9.59 Revenue Growth 0.00 %
Current Ratio 7.61 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -10.63 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 472 M Total Cash Per Share 3.22 Total Debt 47000
Total Debt To Equity 0.0100 Current Ratio 7.61 Book Value Per Share 3.06
All Measures
Short Ratio 1669.00 % Message Board Id finmb_592774643 Shares Short Prior Month 12 M
Return On Equity -0.9217 City New York Uuid d116cec5-659e-37a8-8d49-e874f7dd0477
Previous Close 27.16 First Trade Date Epoch Utc 1 B Book Value 3.06
Beta 0.7090 Total Debt 47000 Volume 712739
Price To Book 9.38 Fifty Two Week Low 24.61 Total Cash Per Share 3.22
Shares Short Previous Month Date 1 B Target Median Price 49.00 Max Age 86400
Recommendation Mean 1.31 Sand P52 Week Change 0.3133 Target Mean Price 48.93
Net Income To Common -323006016 Short Percent Of Float 0.2021 Implied Shares Outstanding 146 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 472 M Next Fiscal Year End 1 B
Held Percent Insiders 0.5570 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 27.16 Target Low Price 36.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 28.99 Open 27.42
Free Cashflow -160827008 State NY Dividend Yield 0.00 %
Return On Assets -0.5454 Time Zone Short Name EST Trailing Eps -2.21
Day Low 27.30 Address1 320 West 37th Street Shares Outstanding 146 M
Price Hint 2 Target High Price 58.00 Website https://immunovant.com
52 Week Change -0.2658 Average Volume 900617 Forward Eps -3.03
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 712.40 %
Is_sp_500 False Regular Market Day High 29.10 Profit Margins 0.00 %
Debt To Equity 0.0100 Fifty Two Week High 45.58 Day High 29.10
Shares Short 13 M Regular Market Open 27.42 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0887
Operating Cashflow -271643008 Currency USD Time Zone Full Name America/New_York
Market Cap 4 B Is_nasdaq_100 False Zip 10018
Quote Type EQUITY Industry Biotechnology Long Name Immunovant, Inc.
Regular Market Day Low 27.30 Held Percent Institutions 0.5462 Current Price 28.73
Address2 6th Floor Enterprise To Ebitda -10.63 Financial Currency USD
Current Ratio 7.61 Industry Disp Biotechnology Number Of Analyst Opinions 15
Country United States Float Shares 65 M Two Hundred Day Average 29.76
Enterprise Value 3 B Forward PE -9.59 Regular Market Volume 712739
Ebitda -352164992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.

Immunovant, Inc. is based in New York, New York.

Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.